Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

NCT00923806 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to poor accrual.

Conditions

Metastatic Cancer

Interventions

BIOLOGICAL: PG13-CEA_TCR (Anti-CEA TCR PBL)
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)